Merck & Co., Inc. is 13.9x more valuable than Roivant Sciences Ltd. by market capitalization ($294.13 B vs $21.12 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ROIV | MRK |
|---|---|---|
| Market cap | $21.12 B | $294.13 B |
| US-listed rank | #603 | #44 |
| Revenue (latest FY) | $8.26M | $65.01B |
| Net income (latest FY) | -$299.77M | $18.25B |
| Net margin | -3629.2% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 868 | 996 |
Merck & Co., Inc. is 13.9x more valuable than Roivant Sciences Ltd. by market capitalization ($294.13 B vs $21.12 B).
In their latest fiscal years, Roivant Sciences Ltd. reported $8.26M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Roivant Sciences Ltd. and Merck & Co., Inc., or browse the full rankings.